膀胱過動症治療市場- 依病情類型（[神經源性、特發性]、治療類型（藥物治療[抗膽鹼能、Beta-3 腎上腺素受體激動劑]、肉毒桿菌治療、神經調節））、年齡層（31-50、51-60） - 全球預測（2024 - 2032）

在治療方案的進步和研發力度的推動下，全球膀胱過動症治療市場在 2024 年至 2032 年間將達到 4.3% 的複合年成長率。藥物創新，例如新藥和先進神經調節技術的開發，為患者提供了更有效和多樣化的治療選擇。對 OAB 根本原因和管理的持續研究推動了改進療法和干涉措施的創建。這種持續的進步提高了治療效果，擴大了行業產品範圍，並滿足了對有效 OAB 解決方案不斷成長的需求。

例如，2024 年 7 月，藥品和保健品監管局 (MHRA) 批准 vibegron (Obgemsa) 用於治療成年患者膀胱過動症候群 (OAB) 症狀。這項進展引入了一種新的治療選擇，擴大了可用於治療 OAB 症狀的治療範圍。此次批准強調了該領域持續的創新，有可能透過滿足有效新療法的需求來推動市場成長。它也反映了對解決和改善膀胱過動症患者護理的更廣泛承諾。

膀胱過動症治療行業根據病情類型、治療類型、年齡層和地區進行分類。

由於老年人此病的盛行率較高，到 2032 年，60 歲以上族群將大幅增加。與年齡相關的膀胱功能變化和相關健康問題發生率的增加導致對有效治療方案的更大需求。隨著人口的成長，針對老年人群的專門治療的需求日益增加。這一趨勢凸顯了 60 歲及以上年齡層靶向膀胱過動症治療的巨大市場潛力。

在有效管理症狀的創新方法的推動下，神經調節領域到 2032 年將取得顯著進展。骶神經刺激和經皮脛神經刺激等技術可透過調節參與膀胱控制的神經活動來提供有針對性的緩解。這些先進的療法提供了重要的好處，包括與傳統療法相比減少了副作用。隨著對微創和有效解決方案的需求不斷成長，神經調節在提供個人化、持久緩解方面的作用推動了其在行業中的主導地位。

由於其先進的醫療基礎設施和該疾病的高盛行率，歐洲膀胱過動症治療市場到 2032 年將保持適度的複合年成長率。該地區強大的醫學研究能力和對創新療法的大量投資促進了該行業的成長。此外，提高意識和獲得專業醫療服務也支持了對有效膀胱過動症治療的需求。歐洲將先進的醫療保健系統和積極的研究相結合，使其成為全球膀胱過動症治療行業的關鍵貢獻者。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 膀胱過動症盛行率上升
    • 人口老化加劇
    • 增加研究投資和活動
    • 提高早期診斷和治療意識
  • 產業陷阱與挑戰
    • 與藥物和治療相關的不良反應
• 成長潛力分析
• 管道分析
• 監管環境
• 波特分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按條件類型，2021 - 2032 年

• 主要趨勢
• 神經源性膀胱過動症
• 特發性膀胱過動症

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 藥物治療
  • 抗膽鹼藥
  • Beta-3 腎上腺素受體激動劑
• 肉毒桿菌治療
• 神經調節
• 其他治療類型

第 7 章：市場估計與預測：按年齡分類，2021 - 2032

• 主要趨勢
• 18-30日
• 31-50
• 51-60
• 60以上

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AbbVie Inc.
• Astellas Pharma Inc.
• Axonics, Inc.
• BlueWind Medical
• Cipla Ltd.
• Endo International plc
• Laborie
• Lupin Ltd.
• Medtronic plc
• Merck & Co.
• Pfizer Inc.
• Sumitomo Pharma America, Inc. (Urovant Sciences)
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd.

Global Overactive Bladder Treatment Market will achieve a 4.3% CAGR between 2024 and 2032, propelled by advancements in treatment options and increased research and development. Innovations in pharmaceuticals, such as the development of new medications and advanced neuromodulation techniques, provide patients with more effective and diverse treatment choices. Ongoing research into the underlying causes and management of OAB fuels the creation of improved therapies and interventions. This continuous progress enhances treatment efficacy, expands industry offerings, and meets the growing demand for effective OAB solutions.

For instance, in July 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved vibegron (Obgemsa) for treating overactive bladder syndrome (OAB) symptoms in adult patients. This development introduces a new therapeutic option, enhancing the range of treatments available for managing OAB symptoms. The approval underscores ongoing innovation in the field, potentially driving market growth by meeting the demand for effective new treatments. It also reflects a broader commitment to addressing and improving care for patients with overactive bladder.

The overactive bladder treatment industry is divided based on the condition type, treatment type, age group, and region.

The 60 above segment will see a considerable surge by 2032, attributed to the higher prevalence of the condition among older adults. Age-related changes in bladder function and an increased incidence of related health issues contribute to a greater demand for effective treatment options. As this demographic grows, the need for specialized therapies tailored to the older population intensifies. This trend highlights the significant market potential within the 60 and above age group for targeted overactive bladder treatments.

The neuromodulation segment will garner notable gains by 2032, driven by its innovative approach to managing symptoms effectively. Techniques such as sacral nerve stimulation and percutaneous tibial nerve stimulation offer targeted relief by modulating nerve activity involved in bladder control. These advanced therapies provide vital benefits, including reduced side effects compared to traditional treatments. As demand for minimally invasive and effective solutions grows, neuromodulation's role in offering personalized, long-lasting relief drives its dominance in the industry.

Europe overactive bladder treatment market will secure a moderate CAGR through 2032, owing to its advanced healthcare infrastructure and high prevalence of the condition. The region's robust medical research capabilities and substantial investment in innovative treatments contribute to industry growth. Additionally, increasing awareness and access to specialized healthcare services support the demand for effective overactive bladder therapies. Europe's combination of sophisticated healthcare systems and active research makes it a key contributor to the global overactive bladder treatment industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of overactive bladder
    • 3.2.1.2 Growing aging population
    • 3.2.1.3 Increasing research investments and activities
    • 3.2.1.4 Growing awareness for early diagnosis and treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects associated with medications and treatment
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porters analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Condition Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Neurogenic bladder overactivity
• 5.3 Idiopathic bladder overactivity

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug therapy
  • 6.2.1 Anticholinergics
  • 6.2.2 Beta-3 adrenoceptor agonists
• 6.3 Botox treatment
• 6.4 Neuromodulation
• 6.5 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 18-30
• 7.3 31-50
• 7.4 51-60
• 7.5 60 above

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Astellas Pharma Inc.
• 9.3 Axonics, Inc.
• 9.4 BlueWind Medical
• 9.5 Cipla Ltd.
• 9.6 Endo International plc
• 9.7 Laborie
• 9.8 Lupin Ltd.
• 9.9 Medtronic plc
• 9.10 Merck & Co.
• 9.11 Pfizer Inc.
• 9.12 Sumitomo Pharma America, Inc. (Urovant Sciences)
• 9.13 Teva Pharmaceutical Industries Ltd.
• 9.14 Viatris Inc.
• 9.15 Zydus Lifesciences Ltd.